Orthonika Limited, a spin-out from Imperial College London, is pleased to announce success in securing funding for development of its novel synthetic total knee meniscus replacement. The company has closed a second round of investment of £675,000 from a group of angel investors alongside a Biomedical Catalyst award and an Industrial Challenge award. The funding is being used to accelerate progress on biomechanical testing and carry out a pre-clinical pilot trial.

Dr Mario Alberto Accardi, Co-Founder and Chief Executive Officer, commented “We are delighted to have raised the funds to bring this revolutionary treatment for meniscus injury into a pre-clinical pilot trial. We are very grateful to our angel investors and Innovate UK for their support.”

Dominique Kleyn, Co-Founder and Chief Operating Officer, added “This investment demonstrates a strong endorsement of our progress in developing a novel solution for meniscus injury and allows us to cement our network of collaborators and suppliers.”

Orthonika brings design and development expertise to exploit a novel approach for the replacement of a damaged meniscus, restoring knee biomechanics and allowing patients to return to an active lifestyle. The goal is to advance the meniscus replacement into a product and obtain regulatory approval for its clinical application.

Here's To Your Health
We're reporting in on the latest in health news, medical research, insurance coverage, plus managing your health and the health of the people you love.
We respect your privacy